Next Generation Sequencing In The Asia Pacific: The Availability & Reimbursement Landscape

Next generation sequencing (NGS) refers to a technology that detects genomic variation that is present at birth or emerges later in life. The introduction of NGS has sparked considerable interest around the world, with demand fueled by the need for better tools to forecast, diagnose, treat, and monitor disease, as well as the advancement of more efficient sequencing technologies.[1] This report describes the availability of NGS in a selection of locations.

NGS provides for the rapid sequencing of a large number of genes at a low cost, which aids in the detection of clinically significant mutations and promotes precision oncology. The NGS test is widely accepted as part of standard cancer care and is being reimbursed in several Western and Asian nations. [2]